MedPath

Randomized Controlled Trial of Rabeprazol Versus Placebo Administration in the Prevention of Esophageal Variceal Bleeding After Esophageal Variceal Ligatio

Phase 2
Conditions
Patients after esophageal variceal ligation (EVL)
Registration Number
JPRN-UMIN000003913
Lead Sponsor
Post-EVL Study Office
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
44
Inclusion Criteria

Not provided

Exclusion Criteria

(1)Hepatocellular carcinoma (2)Refractory ascites and uncontrolled hepatic encephalopathy (3)Active alcoholism before 3 months (4)Portal thrombus (5)Allergy or past adverse reaction to proton pump inhibitors

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
on-bleeding survival time
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath